ACLX
Arcellx Inc

434
Mkt Cap
$5.2B
Volume
73,981.00
52W High
$96.39
52W Low
$47.86
PE Ratio
-22.97
ACLX Fundamentals
Price
$90.51
Prev Close
$89.99
Open
$90.00
50D MA
$84.32
Beta
1.23
Avg. Volume
508,790.13
EPS (Annual)
-$2.00
P/B
11.80
Rev/Employee
$662,184.05
Loading...
Loading...
News
all
press releases
Arcellx (NASDAQ:ACLX) Coverage Initiated at Wolfe Research
Wolfe Research initiated coverage on Arcellx in a report on Tuesday. They set a "peer perform" rating for the company...
MarketBeat·1h ago
News Placeholder
More News
News Placeholder
Insider Selling: Arcellx (NASDAQ:ACLX) Insider Sells $30,600.00 in Stock
Arcellx, Inc. (NASDAQ:ACLX - Get Free Report) insider Christopher Heery sold 340 shares of Arcellx stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average...
MarketBeat·14h ago
News Placeholder
Arcellx to Host Investor Relations Event During the 67th ASH Annual Meeting and Exposition
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today...
Business Wire·18h ago
News Placeholder
Insider Selling: Arcellx (NASDAQ:ACLX) Insider Sells 340 Shares of Stock
Arcellx, Inc. (NASDAQ:ACLX - Get Free Report) insider Christopher Heery sold 340 shares of the firm's stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average...
MarketBeat·1d ago
News Placeholder
Arcellx (NASDAQ:ACLX) Announces Earnings Results
Arcellx (NASDAQ:ACLX - Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($0.99) earnings per share (EPS) for the quarter, beating analysts' consensus estimates...
MarketBeat·13d ago
News Placeholder
Arcellx, Inc. (ACLX) Reports Q3 Loss, Misses Revenue Estimates
Arcellx (ACLX) delivered earnings and revenue surprises of -3.13% and -66.20%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·14d ago
News Placeholder
Kura Oncology (KURA) Reports Q3 Loss, Lags Revenue Estimates
Kura Oncology (KURA) delivered earnings and revenue surprises of -49.12% and -75.72%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·15d ago
News Placeholder
Arcellx, Inc. (ACLX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Arcellx (ACLX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·20d ago
News Placeholder
Arcellx, Inc. (ACLX) Reports Q2 Loss, Misses Revenue Estimates
Arcellx (ACLX) delivered earnings and revenue surprises of +8.74% and -54.93%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Citi initiates coverage on biotech amid improving sentiment in sector
Investing.com -- Citi initiated coverage on small- and mid-cap biotechnology companies on early signs of improving sentiment in a sector weighed down this year by policy uncertainty and weak investor interest.
investing.com·5mo ago

Latest ACLX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.